Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study

BACKGROUND AND AIM: The purpose of this study was to investigate and validate the efficacy of a nomogram model in predicting early objective response rate (ORR) in u-HCC patients receiving a combination of TACE, Lenvatinib, and anti-PD-1 antibody treatment after 3 months (triple therapy). METHOD: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuqun, Wu, Junyi, Wu, Jiayi, Fu, Yangkai, Zeng, Zhenxin, Li, Yinan, Li, Han, Liao, Weijia, Yan, Maolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981935/
https://www.ncbi.nlm.nih.gov/pubmed/36875116
http://dx.doi.org/10.3389/fimmu.2023.1109771

Ejemplares similares

Ejemplares similares